Table 1

Clinical characteristics of head and neck cancer patients

Characteristics

Mutated M6P/IGF2R (n = 30)

Non Mutated M6P/IGF2R (n = 26)

Informative Patients (n = 56)

Excluded Patients(n = 83)


Gender (No.)

Male: 25 (83%)

Male: 23 (89%)

Male: 48 (86%)

Male: 66 (80%)

p = 0.71; p = 0.42

Female: 5 (17%)

Female: 3 (11%)

Female: 8 (14%)

Female: 17 (20%)

Age (Years)

Median: 60.4

Median: 60.9

Median: 61

Median: 60

p = 1.0; p = 0.5

Range: 37–71

Range: 39 – 74

Range: 37 – 74

Range: 30 – 75

Race (No.)

White: 25 (83%)

White: 17 (65%)

White: 42 (75%)

White: 52 (63%)

p = 0.2; p = 0.3

Black: 5 (17%)

Black: 8 (31%)

Black: 13 (23%)

Black: 30 (36%)

Native American: 1 (4%)

Native American: 1 (2%)

Native American: 1 (1%)

Smoking History

Yes: 30 (100%)

Yes: 23 (89%)

Yes: 53 (95%)

Yes: 76 (92%)

p = 0.1; p = 0.5

No: 0 (0%)

No: 3 (11%)

No: 3 (5%)

No: 7 (8%)

Baseline Hgb (g/dL)

Median: 14.2

Median: 14

Median: 14.2

Median: 13.5

p = 0.8; p = 0.06

Range: 11.5 – 17

Range: 9.9 – 16.9

Range: 9.9 – 17.3

Range: 10.8 – 25

Karnofsky Performance

Median: 90

Median: 90

Median: 90

Median: 90

Status p = 0.9; p = 0.2

Range: 60–100

Range: 70 – 100

Range: 60 – 100

Range: 60 – 100

Tumor Resectability

Yes: 18 (60%)

Yes: 14 (53%)

Yes: 32 (57%)

Yes: 49 (59%)

p = 0.8; p = 0.5

No: 12 (40%)

No: 12 (47%)

No: 24 (43%)

No: 34 (41%)

Follow-up (Months)

Median: 29

Median: 52

Median: 38.6

Median: 28.2

Range: 2 – 100

Range: 3–124

Range: 2 – 125

Range: 2 – 97

Treatment (No.)

p = 0.8; p = 0.8

RT alone

17 (57%)

16 (61%)

33 (59%)

46 (55%)

RT + Chemotherapy

13 (43%)

10 (39%)

23 (41%)

37 (45%)

Tumor Stage (No.)

p = 0.4; p = 0.3

T1

0

0

0

1 (1%)

T2

3 (10%)

6 (23%)

9 (16%)

6 (8%)

T3

14 (47%)

11 (42%)

25 (45%)

45 (54%)

T4

13 (43%)

9 (35%)

22 (39%)

30 (36%)

Tx

0

0

0

1 (1%)

Nodal Stage (No.)

p = 0.6; p = 0.2

N0

9 (30%)

8 (31%)

17 (30%)

24 (29%)

N1

7 (23%)

3 (12%)

10 (18%)

15 (18%)

N2

12 (40%)

14 (53%)

26 (46%)

30 (36%)

N3

2 (7%)

1 (4%)

3 (5%)

14 (17%)

Overall Staging (No.)

p = 0.4; p = 0.08

II

0

2 (8%)

2 (4%)

0

III

11 (37%)

7 (27%)

18 (32%)

24 (29%)

IVa

17 (57%)

16 (61%)

33 (59%)

45 (54%)

IVb

2 (7%)

1 (4%)

3 (5%)

14 (17%)

Primary Tumor Site (No.)

p = 0.1; p = 0.07

Base of tongue

7 (23%)

10 (38%)

17 (30%)

15 (18%)

Tonsil

7 (23%)

4 (16%)

11 (20%)

23 (27%)

Larynx

9 (30%)

3 (11%)

12 (21%)

11 (13%)

Hypopharynx

3 (10)

6 (23%)

9 (16%)

17 (21%)

Paranasal Sinuses

0

2 (8%)

2 (4%)

5 (6%)

Oral Cavity

4 (14%)

1 (4%)

5 (9%)

3 (4%)

Nasopharynx

0

0

0

8 (10%)

Unknown

0

0

0

1 (1%)


1p-value for comparison between patients with M6P/IGF2R mutated and non mutated tumors. 2p-value for comparison between the M6P/IGF2R informative patients and excluded patients.

Jamieson et al. BMC Cancer 2003 3:4   doi:10.1186/1471-2407-3-4

Open Data